Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2018 October;109(5) > Minerva Medica 2018 October;109(5):403-5

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

LETTERS TO THE EDITOR   

Minerva Medica 2018 October;109(5):403-5

DOI: 10.23736/S0026-4806.18.05564-7

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Triple therapy: worth the risk?

Bernhard WERNLY 1, Michael LICHTENAUER 1, Uta C. HOPPE 1, Alexander LAUTEN 2, Eliano P. NAVARESE 3, 4, 5, Christian JUNG 6

1 Department of Cardiology, Clinic of Internal Medicine II, Paracelsus Medical University of Salzburg, Salzburg, Austria; 2 Department of Cardiology, Charité - Universitaetsmedizin Berlin, University Heart Center, German Center for Cardiovascular Research (DZHK), Berlin, Germany; 3 Interventional Cardiology and Cardiovascular Medicine Research, Inova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute, Falls Church, VA, USA; 4 SIRIO MEDICINE, Research Network, Falls Church, VA, USA; 5 Cardiovascular Institute, Ludwik Rydygier Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland; 6 Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University of Düsseldorf, Düsseldorf, Germany



top of page